In addition to the loss of VHL, other oncogenic events are required for ccRCC; one being the activation of the phosphoinositide 3-kinase (PI3K)-AKT-mTOR pathway [13,14]. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.